Masaaki is the Co-Founder and CEO of TKG Therapeutics, Inc., an innovative tech company born from the University of Tokyo's pioneering research. The company specializes in developing unique STING agonists that harness the power of nucleic acid medicine to activate innate immunity. Before venturing into biotechnology, Masaaki carved out a distinguished career in the financial markets for almost 20 years, dedicating 8 years to Goldman Sachs.